Spruce Biosciences’ (SPRB) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Spruce Biosciences (NASDAQ:SPRB) in a research note issued to investors on Monday morning, Marketbeat.com reports. They currently have a $220.00 target price on the stock. HC Wainwright also issued estimates for Spruce Biosciences’ Q4 2025 earnings at ($14.95) EPS, FY2025 earnings at ($57.15) EPS, Q1 2026 earnings at ($12.15) EPS, Q2 2026 earnings at ($10.30) EPS, Q3 2026 earnings at ($9.16) EPS, Q4 2026 earnings at ($1.69) EPS and FY2026 earnings at ($32.93) EPS.

SPRB has been the subject of several other research reports. Citizens Jmp upped their price target on shares of Spruce Biosciences from $254.00 to $259.00 and gave the company a “market outperform” rating in a report on Tuesday, November 11th. Wall Street Zen upgraded Spruce Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Leerink Partnrs raised Spruce Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 3rd. Leerink Partners raised Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $160.00 price objective for the company in a research report on Wednesday, December 3rd. Finally, Citigroup reiterated a “market perform” rating on shares of Spruce Biosciences in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $203.08.

Spruce Biosciences Price Performance

Shares of Spruce Biosciences stock opened at $84.42 on Monday. The company has a market capitalization of $90.33 million, a P/E ratio of -0.99 and a beta of 3.45. The business has a 50-day moving average of $105.71 and a two-hundred day moving average of $50.31. Spruce Biosciences has a 1 year low of $4.28 and a 1 year high of $240.00.

Spruce Biosciences (NASDAQ:SPRB) last issued its quarterly earnings data on Monday, November 10th. The company reported ($14.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($15.56) by $0.98. On average, equities analysts anticipate that Spruce Biosciences will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Spruce Biosciences stock. Carlyle Group Inc. acquired a new stake in Spruce Biosciences, Inc. (NASDAQ:SPRB) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 2,896,518 shares of the company’s stock, valued at approximately $24,765,000. Spruce Biosciences accounts for about 0.6% of Carlyle Group Inc.’s portfolio, making the stock its 4th largest position. Carlyle Group Inc. owned about 579.30% of Spruce Biosciences at the end of the most recent quarter. Hedge funds and other institutional investors own 91.71% of the company’s stock.

Key Spruce Biosciences News

Here are the key news stories impacting Spruce Biosciences this week:

• Positive Sentiment: Oppenheimer initiated coverage of Spruce Biosciences with an Outperform, which can attract new buyer interest and institutional attention. Oppenheimer Initiation
• Positive Sentiment: HC Wainwright maintains a Buy rating and a $220 price target on SPRB — a bullish headline that can support the rally and set a high upside reference point for investors. HC Wainwright Report
• Neutral Sentiment: Short-interest data posted for December shows 0 shares and a days-to-cover of 0.0 — this looks like an anomalous or missing-data report (NaN change). If accurate, near-zero short interest would remove a potential short-squeeze dynamic; if erroneous, it should be treated cautiously.
• Negative Sentiment: HC Wainwright’s published EPS schedule forecasts large losses across 2025–2026 (e.g., FY2025: ($57.15), FY2026: ($32.93) per their notes), underlining that the company is expected to remain unprofitable for the foreseeable future — a fundamental risk that could cap gains or prompt volatility if execution or cash concerns surface. HC Wainwright Estimates

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.